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Abstract
Objective: Acromegaly is a rare disease caused by excess growth hormone (GH) production by the pituitary adenoma. 
The skeletal complications of GH and IGF-1 excess include increased bone turnover, increased cortical bone mass and 
deteriorated microarchitecture of trabecular bone, associated with a high risk of vertebral fractures in the presence 
of relatively normal bone mineral density (BMD). We aimed to evaluate tissue-level properties of bone using impact 
microindentation (IMI) in well-controlled patients with acromegaly aged ≥18 years compared to 44 controls from the 
outpatient clinic of the Centre for Bone Quality. 
Design and methods: In this cross-sectional study, bone material strength index (BMSi) was measured in 48 acromegaly 
patients and 44 controls with impact microindentation using the osteoprobe.
Results: Mean age of acromegaly patients (54% male) was 60.2 years (range 37.9–76.5), and 60.5 years (range 39.8–78.6)  
in controls (50% male). Patients with acromegaly and control patients had comparable BMI (28.2 kg/m2 ± 4.7 vs 26.6 kg/
m2 ± 4.3, P = 0.087) and comparable BMD at the lumbar spine (1.04 g/cm2 ± 0.21 vs 1.03 g/cm2 ± 0.13, P = 0.850) and at the 
femoral neck (0.84 g/cm2 ± 0.16 vs 0.80 g/cm2 ± 0.09, P = 0.246). BMSi was significantly lower in acromegaly patients than 
that in controls (79.4 ± 0.7 vs 83.2 ± 0.7; P < 0.001). 
Conclusion: Our data indicates that tissue-level properties of cortical bone are significantly altered in patients with 
controlled acromegaly after reversal of long-term exposure to pathologically high GH and IGF-1 levels. Our findings 
also suggest that methods other than DXA should be considered to evaluate bone fragility in patients  
with acromegaly.
Introduction
Acromegaly is a rare endocrine disease characterized by 
excess circulating growth hormone (GH) and insulin-
like growth factor-1 (IGF-1) levels, usually caused by 
an adenoma of the anterior pituitary gland. GH excess 
results in morbidity of multiple organ systems, including 
generalized tissue hypertrophy, cardio-metabolic disorders 
(diabetes mellitus and hypertension and cardiomyopathy) 
and arthropathy. Acromegaly has been shown to be 
associated with an increased risk of vertebral fractures in 
the presence of a relatively normal bone mineral density 
(BMD), and it has also been shown that these fractures 
may progress despite adequate control of disease activity 
(1, 2, 3, 4, 5). Patients with active acromegaly demonstrate 
high bone turnover associated with increased cortical 
BMD in the presence of stable trabecular bone mass. 
Iliac crest biopsies indeed show an increase in bone 
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remodeling compared to that in healthy controls (6). 
Trabecular connections are lost, due to the high bone 
turnover, resulting in altered bone microarchitecture, 
which also persists after successful induction of remission 
and restoration of bone remodeling rates (7, 8). In a study 
with HRpQCT, structural measurements confirmed this 
altered bone microarchitecture in patients with active as 
well as controlled acromegaly. This included deteriorated 
trabecular microarchitectural parameters in the distal 
radius and distal tibia and increased cortical volumetric 
BMD in the distal tibia in patients with active disease 
(9). Areal BMD is often reported to be normal in these 
patients, although some studies do suggest an association 
with low bone mass (2, 10). Overall, current methods do 
not provide an adequate explanation for the increased 
fracture risk in these patients. However, in a recently 
published study evaluating the association between bone 
microstructure, as measured by high-resolution cone 
beam computed tomography, and vertebral fractures, 
the authors found deteriorated microstructure in both 
the trabecular and the cortical bone compartments of 
acromegaly patients with vertebral fractures compared to 
those without vertebral fractures (11).
There are no published data available on the 
assessment of material properties of cortical bone in 
patients with acromegaly; however, there are published 
data on material properties of trabecular bone in 
patients with acromegaly (12). The technique of impact 
microindentation (IMI) was introduced as a reference 
point indentation method to acquire Bone Material 
Strength index measurements in vivo and is used as a 
surrogate to assess tissue-level properties of bone. Previous 
studies have shown deteriorated material properties in 
postmenopausal women with osteoporotic fractures, 
atypical femoral fractures, with type 2 diabetes mellitus 
and in patients with fragility fractures (13, 14, 15, 16). 
Although IMI reflects cortical bone properties rather 
than trabecular bone properties, there is evidence that 
the elevated GH levels seen in acromegaly affect both 
compartments (6, 11). As current diagnostic tools do not 
adequately identify acromegaly patients who are at high 
risk for vertebral fractures, new methods are needed.
In this study, we aimed to evaluate previously 
reported findings of poor bone material properties in 
patients with acromegaly by evaluating whether BMSi is 
different between patients with acromegaly in remission 
and controls without acromegaly. In addition, we also 
aimed to evaluate whether BMSi was different in patients 
with acromegaly, with or without vertebral fractures.
Patients and methods
Study design
We performed a cross-sectional study to compare Bone 
Material Strength index (BMSi) between patients with 
well-controlled acromegaly and non-acromegaly control 
patients with osteopenia or normal bone mineral density 
(BMD), with or without fractures. Patients were studied 
at the outpatient clinics of the Leiden University Medical 
Center. The Medical Ethics Committee of the Leiden 
University Medical Center reviewed and approved the 
study, and all patients gave written informed consent to 
participate in the study.
Patients with acromegaly
All patients aged 18 years or older with well-controlled 
acromegaly attending the outpatient clinic of the 
Department of Endocrinology of the Leiden University 
Medical Center were identified from hospital records. 
170 patients with acromegaly, 73 of whom fulfilled the 
inclusion criteria and were invited to participate in the 
study. Forty-eight patients responded positively and were 
included in the study (Fig. 1). Of these patients, 26 (54%) 
had been evaluated in previously reported studies from 
our center (2, 4).
In this study, well-controlled acromegaly was 
defined as serum IGF-1 levels within the normal age 
range after surgery, radiotherapy, medical treatment or 
a combination thereof, and when required, additional 
confirmation of remission from glucose-suppression tests. 
Oral glucose tolerance tests were performed yearly to 
assess disease activity, except in patients receiving medical 
treatment (17). 
Controls
Controls were recruited from the outpatient clinic of the 
Centre for Bone Quality or from the regional Fracture 
Liaison Service of the Leiden University Medical Center 
and were matched on age and BMD. A number of these 
control patients have also been reported in an earlier 
study (n = 12) (16). Control patients who reported fragility 
fractures or who had grade 2 or 3 morphometric vertebral 
fractures were excluded from the study. A fragility fracture 
was defined as any low-energy fracture, excluding those of 
the hands, feet and skull. Control patients with fractures 
after a high-energy trauma or grade 1 morphometric 
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Both acromegaly and non-acromegaly control 
patients were excluded if they had a metabolic bone 
disease other than osteoporosis; any untreated endocrine 
disorder; severe liver insufficiency or chronic kidney 
disease stage IV or V; have had bilateral hip replacement; 
were currently using aromatase inhibitors or androgen 
deprivation therapy; and were currently using or had used 
bisphosphonates, denosumab, selective estrogen receptor 
modulators (SERMs), strontium ranelate or recombinant 
PTH. Furthermore, patients were excluded if they had a 
localized infection of the tibia or were unable to provide 
informed consent. Current or past use of glucocorticoids 
was also an exclusion criterion with the exception 
of hydrocortisone supplementation for secondary 
adrenal insufficiency.
Methods
Medical history data including date of start of treatment, 
type of treatment (surgery, radiotherapy, medication 
use or combined), date of normalization of IGF-1, data 
on other pituitary function tests, menopausal status, 
previous or current medication use and fracture history 
were collected at the time of inclusion in the study. Daily 
calcium intake was calculated and clinical risk factors for 
fracture as used in the FRAX algorithm were obtained 
from each patient.
Laboratory investigations
Serum calcium, phosphate, albumin and creatinine were 
measured using semi-automated techniques. Plasma 
intact PTH was measured by the IMMULITE 2500 
(Siemens Diagnostics), and serum 25-hydroxyvitamin D 
was measured using the 25-OH-vitamin D TOTAL assay 
(DiaSorin D.A./N.V.). Procollagen type 1 amino-terminal 
propeptide (P1NP) and β-crosslaps were measured by an 
electrochemoluminescent immunoassay with a Modular 
Analytics E-170 system (Roche Diagnostics).
Serum IGF-1 levels (nmol/L) were measured using an 
immunometric technique on an IMMULITE 2500 system 
(Diagnostic Products Corporation, Deerfield, IL, USA). 
The intra-assay variations at mean plasma levels of 8 and 
75 nmol/L were 5.0% and 7.5% respectively. IGF-1 levels 
were expressed as SDS, using λ-μ-σ smoothed reference 
curves based on measurements in 906 healthy individuals 
(18, 19).
Serum GH levels were measured with a immuno-
fluorometric assay (Siemens Diagnostics) calibrated against 
World Health Organization (WHO) National Institute for 
Biological Standards and Control (NIBSC) 2nd International 
Standard 98/574. Values were multiplied by 1.02.
Bone mineral density
BMD was measured at the lumbar vertebrae (L1–L4) 
and at the left and right femoral neck using dual-energy 
Figure 1
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X-ray absorptiometry (DXA) (Hologic QDR Discovery A 
(Hologic, Bedford, MA, USA)) at the time of indentation. 
NHANES III reference values compatible with reference 
values of the Dutch population were used to calculate 
T-scores. Normal bone mineral density, osteopenia or 
osteoporosis was diagnosed using WHO criteria. 
Spinal radiographs
Conventional antero-posterior and lateral radiographs of 
the thoracic and lumbar spine were performed following 
standard protocols, at a focus-detector distance of 115 cm, 
with the detector centralized on Th7 for the thoracic spine 
and on L3 for the lumbar spine at the time of inclusion. 
The semi-quantitative method of Genant was used to 
assess the presence and grading of vertebral fractures. 
Vertebral fractures were scored as grade 1 (reduction in 
anterior, middle and/or posterior height between 20% 
and 25%), grade 2 (reduction in anterior, middle and/
or posterior height between 25% and 40%) or grade 3 
(reduction >40% in anterior, middle and/or posterior 
height) (20), without a history of high-energy trauma.
Radiographs were independently assessed by two of 
the authors (N A-D and H K). Consensus was reached in 
case of difference in assessment.
Impact microindentation
A reference point indentation tool, the Osteoprobe, 
specifically designed for in vivo measurements of Bone 
Material Strength index (BMSi) in humans and large 
animals (21), was used as a surrogate to evaluate bone 
material properties (16). Impact microindentation is 
performed on the midshaft of the tibia by inserting a test 
probe in the skin until the bone surface is reached. By 
indenting the bone surface, the resistance of the bone 
tissue to fracture is evaluated (Fig.  2). The first studies 
performed in humans with a previous version of the 
technique have shown that postmenopausal women 
with osteoporotic fracture and with atypical femoral 
fracture have significantly higher indentation distance 
increase (IDI) than controls without fractures. Further 
studies using the impact microindentation technique 
demonstrated that patients with suspected deteriorated 
material properties such as patients with fragility fractures 
or patients with type 2 diabetes mellitus had significantly 
lower BMSi values (13, 14, 15, 16). The measurement site 
was defined as the mean distance between the distal apex 
of the patella and medial malleolus. Local anesthesia 
(Lidocaine 1%) was applied at the measurement site. 
The test probe was inserted at the site of interest after 
successful anesthesia of the skin and periosteum and was 
pushed gently until it reached the bone surface. It was 
ensured that the test probe was always perpendicular to 
the bone surface during measurements. The operator was 
not allowed to check the measurements on the computer 
screen before these were classified as ‘well performed’, 
‘adequate’ or ‘poorly performed’. Measurements were 
classified as ‘poorly performed’ if the measurement probe 
slipped or if the subject moved his/her leg. At least five 
adequate measurements were obtained from each patient, 
followed by five additional measurements performed on 
a polymethylmethacrylate (PMMA) calibration phantom. 
The number of measurements ranged from 10 to 24. The 
resultant outcome BMSi was defined as 100 times the 
ratio of the harmonic mean indentation distance increase 
from impact into the PMMA calibration phantom divided 
by the indentation distance increase from impact into 
bone (21). 
The intra-observer coefficient of variation (CV) was 
2.2%. Ten subjects were measured twice on the same 
Figure 2
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leg. The distance between the two measurement sites 
was 2 cm. 
Statistical analysis
Analyses were performed using SPSS software for Windows 
(version 23.0; SPSS Inc.). Data are expressed as mean ± s.d. 
unless otherwise stated. Normality assumptions were 
checked by the evaluation of normality plots and by 
inspection of histograms of residuals from miscellaneous 
regression models. Differences between groups were 
assessed using a two-sample t tests or chi-square tests. 
Pearson/Spearman correlation coefficients were used to 
express correlations between IGF-1 levels, duration of 
disease remission and BMSi values. Analysis of variance 
models with BMSi as outcome variable adjusted for age was 
used to compare BMSi values between patients and controls. 
Differences were considered to be significant at P < 0.05. 
Results
We included 48 patients with acromegaly and 44 controls 
who were comparable in gender, age, BMI and BMD at 
the lumbar spine and at the femoral neck (Table 1). The 
two groups were also comparable regarding the number 
of patients who had sustained a non-vertebral fracture, 11 
(23%) in acromegaly patients and 11 (25%) in controls. 
There were more acromegaly patients with a vertebral 
deformity than controls (28 (58%) vs 7 (16%); P < 0.001).
In the acromegaly group, 27 patients (56%) were in 
remission after surgery, 7 of whom received additional 
radiotherapy. 21 (44%) patients were controlled with 
ongoing medical treatment with somatostatin analogs 
only (n = 14), Pegvisomant, a GH receptor antagonist, 
only (n = 3) or combination therapy (n = 4), 1 of whom 
had received radiotherapy, 16 of whom had surgery and 
4 of whom had both. The mean duration of acromegaly 
remission was 16.1 years (range 0.5–37.8 years). There 
were 8 patients with type 2 diabetes mellitus, 3 of whom 
were conservatively treated and 5 received drug therapy 
(4 oral anti-diabetic agents and 1 insulin therapy), 11 
with treated hypothyroidism, 10 with treated adrenal 
insufficiency and 9 with treated hypogonadism.
Bone Material Strength index
Patients with acromegaly had significantly lower BMSi 
values compared to controls (79.4 ± 0.7 vs 83.2 ± 0.7; 
P < 0.001), also after adjustment for age (79.4 ± 0.7 vs 
83.2 ± 0.7; P < 0.001) (Fig.  3). This finding remained if 
patients with type 2 diabetes mellitus were excluded 
(79.2 ± 0.8 vs 83.2 ± 0.7; P < 0.001). Although numbers 
Table 1  Characteristics of patients with acromegaly and non-acromegaly controls. Values are expressed as mean ± s.d.
 Acromegaly (n = 48) Control (n = 44) P-value
Age (years) 60.2 ± 11.0 60.5 ± 8.5 0.849
Male/female 26/22 22/22 0.689
BMI (kg/m2) 28.2 ± 4.7 26.6 ± 4.3 0.087
Fracture 11 (23%) 11 (25%) 0.815
Vertebral fracture 28 (58%) 7 (16%) <0.001
Grade 1 28 (58%) 7 (16%) <0.001
Grade 2/3 11 (23%) 0 0.001
Smoking (%) 6 (13%) 8 (18%) 0.449
Alcohol use >3 IU/day (%) 5 (10%) 8 (18%) 0.304
Glucocorticoids (%) 8 (17%) 5 (11%) 0.466
PTH (pmol/L) 4.6 ± 2.8 3.3 ± 1.5 0.014
Calcium (mmol/L) 2.38 ± 0.11 2.39 ± 0.10 0.473
25-OH D (nmol/L) 67.3 ± 28.5 67.3 ± 27.6 0.944
Creatinine (µmol/L) 78.8 ± 14.3 76.1 ± 18.4 0.471
GH (mU/L) 4.0 ± 5.5 –  
IGF-1 (nmol/L) 19.5 ± 7.6 –  
IGF-1 s.d. 1.0 ± 1.3 –  
LS BMD (g/cm2) 1.04 ± 0.21 1.03 ± 0.13 0.850
T-score LS −0.3 ± 1.8 −0.3 ± 1.2 0.963
FN BMD (g/cm2) 0.84 ± 0.16 0.80 ± 0.09 0.246
T-score FN −0.6 ± 1.2 −0.8 ± 0.8 0.358
BMI, body mass index; IU, international unit; PTH, parathyroid hormone; GH, growth hormone; IGF-1, insulin-like growth factor 1;  
LS, lumbar spine; FN, femoral neck; BMD, bone mineral density.
Reference range: PTH (0.7–8.0 pmol/L); Calcium (2.15–2.55 mmol/L); 25-OH D (50–250 nmol/L); Creatinine (64–104 µmol/L for male, 49–90 µmol/L for 
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are small, there was no statistically significant difference 
in BMSi in patients with acromegaly regardless of the 
therapeutic intervention used to normalize IGF-1 levels 
(surgery: 81.1 ± 1.0, surgery and radiotherapy: 77.9 ± 1.7, 
medical treatment: 78.4 ± 1.0; P = 0.114).
Factors affecting BMSi in acromegaly patients
In the group of patients with acromegaly, there was 
a significant relationship between BMSi and age 
(r = 0.291, P = 0.045). BMSi was not correlated with other 
clinical characteristics including BMI and duration of 
remission. There was also no relationship between BMSi 
and any biochemical parameter measured including 
parameters of calcium metabolism, serum levels of 
GH and IGF-1, gonadal hormone status or with BMD. 
There was no difference in BMSi values between male 
or female patients (79.5 ± 0.9 vs 79.2 ± 1.0; P = 0.804) 
or between patients with or without a non-vertebral 
fracture (80.2 ± 1.4 vs 79.1 ± 0.8; P = 0.511). There 
was no statistically significant difference in BMSi 
between patients with (n = 28) or without a vertebral 
fracture (n = 20); Supplementary Fig. 1 (see section on 
supplementary data given at the end of this article), 
also in the comparison between patients with Genant 
≥ grade 2 vertebral fractures (n = 11) and patients with 
Genant ≤ grade 1 vertebral fractures (n = 37) (80.3 ± 1.4 
vs 79.1 ± 0.8; P = 0.466). 
In the control group, there was a significant inverse 
relationship between BMSi and age (r = −0.457, P = 0.002), 
but no relationship between BMSi and any other 
parameter measured, including BMD.
Discussion
To our knowledge, this is the first study examining tissue-
level properties of cortical bone in patients with well-
controlled acromegaly, previously shown to be at high risk 
for vertebral fractures independently of BMD. Our data 
show significantly lower Bone Material Strength index 
(BMSi) values in patients with well-controlled acromegaly 
than those in controls with comparable age and BMD. 
There was no difference in BMSi within the group of 
patients with acromegaly, in the presence or absence of 
vertebral fractures or in the presence or absence of treated 
hypogonadism.
The reported prevalence of vertebral fractures in 
patients with acromegaly is high, ranging from 53% to 
59% (1, 2, 10). Longitudinal data also show that vertebral 
fractures continue to progress in controlled disease 
in patients both with and without previous vertebral 
fractures (4, 5). This increased vertebral fracture risk in the 
presence of normal or high-normal BMD in patients with 
well-controlled acromegaly suggests that components 
other than bone mass may influence bone strength in 
these patients, such as bone microarchitecture or bone 
material properties. Indeed, histological findings from 
bone biopsies of the iliac crest performed in patients 
with active acromegaly confirm this suggestion by 
showing altered histomorphometric parameters of bone, 
particularly at cortical sites (6). During active acromegaly, 
bone turnover is increased, and this is associated with 
an increase in cortical bone mass. Trabecular bone mass 
remains stable although trabecular connections are lost 
due to the high bone turnover (6, 7, 8). Further reported 
data have also shown an increase in the diameter of 
trabeculae, suggesting microarchitectural changes in the 
trabecular compartment of bone (22). These findings 
were further confirmed in a study using HRpQCT, which 
demonstrated altered microarchitecture of trabecular 
bone in eugonadal acromegalic patients compared to 
those in healthy controls (9). The observations from the 
same study regarding the cortical compartment appear to 
be in contrast with the findings from our study, as cortical 
volumetric BMD was increased in active acromegalic 
patients. However, these patients were compared with 
patients with controlled acromegaly, and our cohort 
consists of well-controlled acromegaly patients only.
A recent study in transgenic bGH mice demonstrated 
poor microarchitecture of both cortical and trabecular 
compartments of the tibia. This is an animal model with 
pathologically elevated GH levels occurring in utero 
and in adult life. Although this mouse model develops 
Figure 3
(A) Mean femoral neck Bone Mineral Density (FN BMD) 
and (B) Bone Material Strength index (BMSi) in patients with 
acromegaly and non-acromegaly controls. Data are shown in 
box-whisker plots and statistical differences are displayed for 
BMSi. Boxes indicate median and inter-quantile range. Bars 
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increased GH levels during skeletal development and is 
therefore not fully comparable with the manifestation 
of GH excess after epiphyseal closure in acromegaly, 
it may provide interesting observations on the effect 
of GH on the skeleton. The bGH mice were shown to 
have a significantly lower trabecular number and lower 
trabecular thickness than control mice, in the presence of 
overall larger bones and increased tibia length. bGH mice 
were also found to have increased cortical bone perimeter 
and cross-sectional area in the tibia, compared with 
control mice, despite lower cortical bone thickness (23). 
Cortical BMD was also significantly lower in the vertebrae 
of bGH mice compared to that in control mice. Vertebral 
trabecular BMD was comparable but trabecular thickness 
was decreased. Mechanical tests performed on the femora 
showed significantly lower mechanical properties, 
including ultimate stress and Young’s modulus, in bGH 
mice compared to littermate controls. These results 
suggest that the cortical compartment in vertebrae is 
perhaps more affected than its trabecular compartment 
as a result of exposure to excess growth hormone. These 
data may provide some further understanding of our 
finding of a lower Bone Material Strength index, which 
mainly measures cortical bone properties, in patients with 
acromegaly with and without fractures. 
The observation that BMSi of acromegaly patients 
with vertebral fractures was not statistically different from 
BMSi of acromegaly patients without vertebral fractures 
might be in keeping with previous suggestions that 
acromegaly affects not only the trabecular compartment 
but also the cortical compartment. For instance, 
Vallassi  et  al. reported that both cortical and trabecular 
volumetric BMD were reduced at the proximal femur in 
35 acromegaly patients, regardless of gender, gonadal 
status and disease activity (24). Recently, Maffezzoni et al. 
reported in 40 patients with acromegaly that those 
with vertebral fractures (n = 15) had lower bone volume/
trabecular volume ratio, greater mean trabecular 
separation and higher cortical porosity compared to those 
without vertebral fractures (n = 25) (11). However, as is 
also seen in our study, group sizes are small due to the 
rarity of the disease and preclude firm conclusions. 
Impact microindentation is an emerging reference 
point indentation technique that measures tissue-level 
properties of cortical bone in vivo at the midshaft of the 
tibia, thus reflecting tissue-level properties of cortical 
rather than trabecular bone. Although this technique 
appears as a promising alternative to assess bone fragility, 
data on fractures (including vertebral fractures) and 
Bone Material Strength index are relatively limited. 
A preliminary report of postmenopausal women with (49% 
vertebral fracture, 51% non-vertebral fracture) or without 
fractures found lower BMSi values in fracture patients and 
a significant inverse relationship between BMSi and grade 
of vertebral fracture (25), whereas a recent study in elderly 
community-dwelling women showed no relationship 
between prevalent vertebral fractures and BMSi (26). 
Within our own cohort of patients with low bone mass 
and fragility fractures, we demonstrated that BMSi was 
low irrespective of the type of fracture: vertebral, non-
vertebral or a combination of the two fracture types (27). 
The difference in BMSi between patient groups (including 
fracture patients) and controls in reported literature is 
variable from 4.5% up to 9.2% (15, 16, 25, 28). Although 
our findings are in keeping with those from other groups, 
the predictive value remains to be determined.
This study has strengths as well as limitations. A major 
strength of the study is having had access to a large 
cohort of well-characterized patients with acromegaly, 
all hormonally and metabolically well controlled. A 
limitation of the study is the cross-sectional design. It 
remains to be established whether BMSi is a predictor for 
vertebral fractures in acromegaly patients in prospective 
studies. Also, we were only able to obtain areal BMD 
data from all patients but not volumetric BMD in any. 
GH significantly increases the size of the skeleton in 
patients with acromegaly and areal BMD does not adjust 
for the size of bone. Although acromegaly is associated 
with comorbidities such as type 2 diabetes mellitus and 
hypogonadism, which in itself may contribute to bone 
fragility, all endocrine deficiencies were adequately 
supplemented and diabetes was well controlled by their 
treating physician as required. Lastly, patients with a 
very high fracture risk could not be included in this 
study, because these patients were currently or had been 
previously treated with bone-modifying agents. 
Findings from our study add to the accumulating 
evidence for the association of acromegaly with structural 
changes of bone, also after adequate control of growth 
hormone production. This is in keeping with findings from 
two recent studies that reported a decrease in trabecular 
bone score (TBS) in the presence of an increase in lumbar 
spine BMD after successful treatment of acromegaly (29), 
and a decrease in cortical and trabecular volumetric BMD 
measured at the femur, independently of acromegaly 
disease status (24). 
In keeping with our previous observation, we found 
a strong inverse relationship between BMSi and age 
in our control group. In contrast, we found a positive 
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acromegaly. A possible explanation of this contrasting 
finding is that older patients had longer remission periods 
and the skeleton may have had more time to recover 
from the effects of high GH levels. This may suggest that 
acromegaly patients with more recent exposure of high 
GH levels (the young patients with acromegaly) have 
lower BMSi values than patients with acromegaly with 
longer duration of remission. However, we did not find a 
relationship between BMSi and the duration of remission 
in our series (r =  0.220, P = 0.133). There was no difference 
in BMSi values between men and women in the group of 
acromegaly patients and in the control group. Although 
skeletal health has been shown to differ between the sexes, 
this observation is in keeping with other data on BMSi 
previously reported by our group (16) and another group 
(30), and partly in keeping with a study that investigated 
male and female HIV patients and controls and observed 
lower BMSi values in female HIV patients compared to 
male patients but comparable BMSi values between male 
and female controls (31).
In conclusion, we demonstrate that BMSi is 
significantly lower in patients with well-controlled 
acromegaly compared to controls. These data indicate 
that tissue-level properties of cortical bone remain 
significantly altered after cessation of long-term exposure 
to pathologically high GH and IGF-1 levels, probably 
contributing to the previously demonstrated ongoing 
increased risk for vertebral fractures. Future prospective 
studies addressing the skeletal complications of acromegaly 
should incorporate the study of microarchitecture and 
material properties of bone in addition to bone mass 
measurements. 
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